Positive Results of Clinical Trials - Report on TRACON Pharmaceuticals

ACI Association has initiated research coverage on TRACON Pharmaceuticals, Inc.

. Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members. Today, membership is open to readers on a complementary basis at the following URL: http://www.aciassociation.com/?c=TCON Highlights from our TCON Report include: Clinical Trial Results - On June 1, 2015, TRACON Pharmaceuticals reported positive results from two separate clinical trials combining TRC105 with approved VEGF inhibitors. The trial showed that complete responses were observed in two patients with angiosarcoma in TRC105 combined with Votrient sarcoma study. Data from the trials were presented at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting in Chicago. TRC105 in Combination with Votrient - The first study of the trial was the dose escalation Phase 1b portion of a Phase 1b/2 study of TRC105 in combination with Votrient® (pazopanib) in 18 patients with advanced soft tissue sarcomas. Minimum one prior chemotherapy regimen was received, and prior treatment with Votrient was allowed to all patients in the Phase 1b study. In the Phase 1b study, on an average, patients had received two prior therapies which ranged from one to seven. All patients were treated with the combination of TRC105 given once weekly (8 or 10 mg/kg) and Votrient at its approved dose of 800 mg per day. TRC105 in Combination with Nexavar - Updated data was presented for the dose escalation Phase 1b portion of a Phase 1b/2 study of TRC105 in combination with Nexavar® (sorafenib) in 20 patients with liver cancer, by the National Cancer Institute (NCI). Patients had compensated liver dysfunction and had not received prior treatment with Nexavar. All 20 patients enrolled in the clinical trial were treated with the combination of TRC105 given once every two weeks (3, 6, 10 or 15 mg/kg) and Nexavar at its approved dose of 400 mg given twice daily. Views of Management - Commenting on the clinical trial, Charles Theuer, M.D., Ph.D, President and CEO of TRACON said, "We continue to see encouraging data for TRC105 in combination with VEGF inhibitors that support targeting the endoglin and VEGF pathways simultaneously to deliver improved patient outcomes." To find out how this influences our rating on TRACON Pharmaceuticals, Inc. read the full report in its entirety here: http://www.aciassociation.com/?c=TCON